Quick Answer
REGENXBIO Inc. reported Total Assets of $453.03 million for the year ending 2025.
- REGENXBIO Inc. showed a decrease of -2.8% in Total Assets from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $227.31 million | Q1 2016: $214.98 million | Q2 2016: $206.07 million | Q3 2016: $195.98 million | Q1 2017: $224.13 million | Q2 2017: $224.38 million | Q3 2017: $209.26 million | Q1 2018: $317.22 million | Q2 2018: $335.99 million | Q3 2018: $514.98 million | Q1 2019: $519.03 million | Q2 2019: $529.14 million | Q3 2019: $509.24 million | Q1 2020: $463.94 million | Q2 2020: $449.74 million | Q3 2020: $541.17 million | Q1 2021: $879.44 million | Q2 2021: $836.40 million | Q3 2021: $800.40 million | Q1 2022: $1.03 billion | Q2 2022: $953.44 million | Q3 2022: $883.79 million | Q1 2023: $747.83 million | Q2 2023: $682.46 million | Q3 2023: $633.79 million | Q1 2024: $629.22 million | Q2 2024: $569.38 million | Q3 2024: $519.11 million | Q1 2025: $490.93 million | Q2 2025: $581.03 million | Q3 2025: $525.20 million.
- Over the full 12 years of available data (2014 to 2025), REGENXBIO Inc.'s Total Assets has grown by 12,877.1%.
- Historical annual values: Fiscal year 2025: $453.03 million | Fiscal year 2024: $465.99 million | Fiscal year 2023: $573.97 million | Fiscal year 2022: $833.27 million | Fiscal year 2021: $1.11 billion | Fiscal year 2020: $708.16 million | Fiscal year 2019: $497.91 million | Fiscal year 2018: $543.81 million | Fiscal year 2017: $198.68 million | Fiscal year 2016: $172.73 million | Fiscal year 2015: $221.38 million | Fiscal year 2014: $3.49 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: